{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T21:53:51Z","timestamp":1784238831407,"version":"3.55.0"},"reference-count":22,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2025,5,26]],"date-time":"2025-05-26T00:00:00Z","timestamp":1748217600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Asia-Pac J Clncl Oncology"],"published-print":{"date-parts":[[2025,12]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      Addition of olanzapine to NK\u20101 receptor antagonist regimen improves chemotherapy\u2010induced nausea and vomiting (CINV) prevention for highly emetogenic chemotherapies (HECs). However, the benefit of addition of NK\u20101 receptor antagonist to olanzapine regimen has not been demonstrated. This study compared the efficacy of upfront and subsequent addition of netupitant\u2010 to olanzapine\u2010containing regimen for preventing CINV from high\u2010dose cisplatin (\u2265 75 mg\/m\n                      <jats:sup>2<\/jats:sup>\n                      ).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Patient and Methods<\/jats:title>\n                    <jats:p>The double\u2010blind placebo\u2010controlled trial randomized patients receiving high\u2010dose cisplatin to upfront and subsequent netupitant arms. In upfront netupitant arm, patients received NEPA (a combination of netupitant and palonosetron), dexamethasone, and olanzapine since first cycle. In subsequent netupitant arm, patients received olanzapine, dexamethasone, and ondansetron in first cycle but received NEPA, dexamethasone, and olanzapine in second cycle if no complete response (CR). After preplanned analysis, the initial dexamethasone dose in netupitant regimen was modified from 4 to 8 mg on Days 2\u20134. The primary endpoint was the overall CR rate of two cycles.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Between January 2019 and December 2020, 51 and 49 patients were randomly assigned to upfront and subsequent netupitant arms, respectively. CR rates in acute (0\u201324 h), delayed (&gt; 24\u2013120 h), and overall periods were 93.0% versus 77.4% (\n                      <jats:italic>p =<\/jats:italic>\n                      0.003), 75.5% versus 68.8% (\n                      <jats:italic>p =<\/jats:italic>\n                      0.31), and 73.3% and 67.7% (\n                      <jats:italic>p =<\/jats:italic>\n                      0.34) in upfront and subsequent netupitant arms, respectively. After amendment to increase dexamethasone in netupitant regimen, first\u2010cycle CR rates in acute, delayed, and overall periods were 95.2% versus 87.7% (\n                      <jats:italic>p =<\/jats:italic>\n                      0.34), 85.7% versus 73.5% (\n                      <jats:italic>p =<\/jats:italic>\n                      0.26), and 85.7% and 69.4% (\n                      <jats:italic>p =<\/jats:italic>\n                      0.26) in 4\u2010drug and 3\u2010drug groups, respectively. Among 15 patients crossing over to receive netupitant regimen in second cycle, CR was 46.6%.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>In this Phase II trial, there was no significant improvement in overall CR when patients received upfront netupitant compared to subsequent addition of netupitant to an olanzapine regimen in patients receiving high\u2010dose cisplatin chemotherapy.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/ajco.14192","type":"journal-article","created":{"date-parts":[[2025,5,26]],"date-time":"2025-05-26T23:28:59Z","timestamp":1748302139000},"page":"631-638","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["The Double\u2010Blind Placebo\u2010Controlled Study Comparing Upfront and Subsequent Netupitant in Addition to Olanzapine\u2010Containing Regimen for Prevention of High\u2010Dose Cisplatin\u2010Induced Nausea\/Vomiting"],"prefix":"10.1111","volume":"21","author":[{"given":"Chanida","family":"Vinayanuwattikun","sequence":"first","affiliation":[{"name":"Division of Medical Oncology, Department of Medicine, Faculty of Medicine Chulalongkorn University and King Chulalongkorn Memorial Hospital  Bangkok Thailand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chalermchai","family":"Lertanansit","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology, Department of Medicine, Faculty of Medicine Chulalongkorn University and King Chulalongkorn Memorial Hospital  Bangkok Thailand"},{"name":"Surin Hospital  Surin Thailand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wasamol","family":"Mahaparn","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology, Department of Medicine, Faculty of Medicine Chulalongkorn University and King Chulalongkorn Memorial Hospital  Bangkok Thailand"},{"name":"Piyavate Hospital, Bang Kapi, Huai Khwang  Bangkok Thailand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Attapol","family":"Chotirut","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology, Department of Medicine, Faculty of Medicine Chulalongkorn University and King Chulalongkorn Memorial Hospital  Bangkok Thailand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicha","family":"Zungsontiporn","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology, Department of Medicine, Faculty of Medicine Chulalongkorn University and King Chulalongkorn Memorial Hospital  Bangkok Thailand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suleepon","family":"Uttamapinan","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology, Department of Medicine, Faculty of Medicine Chulalongkorn University and King Chulalongkorn Memorial Hospital  Bangkok Thailand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nattaya","family":"Sintawichai","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology, Department of Medicine, Faculty of Medicine Chulalongkorn University and King Chulalongkorn Memorial Hospital  Bangkok Thailand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Piyada","family":"Sitthideatphaiboon","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology, Department of Medicine, Faculty of Medicine Chulalongkorn University and King Chulalongkorn Memorial Hospital  Bangkok Thailand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Virote","family":"Sriuranpong","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology, Department of Medicine, Faculty of Medicine Chulalongkorn University and King Chulalongkorn Memorial Hospital  Bangkok Thailand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suebpong","family":"Tanasanvimon","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology, Department of Medicine, Faculty of Medicine Chulalongkorn University and King Chulalongkorn Memorial Hospital  Bangkok Thailand"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2025,5,26]]},"reference":[{"key":"e_1_2_12_2_1","unstructured":"M. J.Bergexr R.Agarwal S.Anand et\u00a0al. NCCN guidelines version 1.2023 antiemesis continue http:\/\/www.nccn. (2023)."},{"key":"e_1_2_12_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2023.102195"},{"key":"e_1_2_12_4_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.01296"},{"key":"e_1_2_12_5_1","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2014-0229"},{"key":"e_1_2_12_6_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdu110"},{"key":"e_1_2_12_7_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-016-3502-x"},{"key":"e_1_2_12_8_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdx698"},{"key":"e_1_2_12_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2017.02.017"},{"key":"e_1_2_12_10_1","doi-asserted-by":"publisher","DOI":"10.18549\/PharmPract.2017.01.877"},{"key":"e_1_2_12_11_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10147-019-01570-3"},{"key":"e_1_2_12_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.suponc.2011.05.002"},{"key":"e_1_2_12_13_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1515725"},{"key":"e_1_2_12_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(19)30678-3"},{"key":"e_1_2_12_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2022.101771"},{"key":"e_1_2_12_16_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-013-1855-y"},{"key":"e_1_2_12_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0009-9236(03)00066-3"},{"key":"e_1_2_12_18_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-020-05588-6"},{"key":"e_1_2_12_19_1","doi-asserted-by":"publisher","DOI":"10.2147\/CMAR.S280995"},{"key":"e_1_2_12_20_1","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2019-0133"},{"key":"e_1_2_12_21_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.74.4375"},{"key":"e_1_2_12_22_1","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2018-0140"},{"key":"e_1_2_12_23_1","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2017-0378"}],"container-title":["Asia-Pacific Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ajco.14192","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T20:31:45Z","timestamp":1762201905000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/ajco.14192"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,26]]},"references-count":22,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["10.1111\/ajco.14192"],"URL":"https:\/\/doi.org\/10.1111\/ajco.14192","archive":["Portico"],"relation":{},"ISSN":["1743-7555","1743-7563"],"issn-type":[{"value":"1743-7555","type":"print"},{"value":"1743-7563","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,26]]},"assertion":[{"value":"2025-05-26","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}